Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience

被引：0
|
作者：
Lutrino, E. S. [1 ]
Orlando, L. [1 ]
Giordano, G. [2 ]
Zamagni, C. [3 ]
Caliolo, C. [1 ]
Febbraro, A. [4 ]
Giampaglia, M. [5 ]
Dima, G. [6 ]
Quaranta, A. [1 ]
Scavelli, C. [7 ]
Bilancia, D. [5 ]
Filippelli, G. [6 ]
Fontanella, C. [8 ]
Schiavone, P. [1 ]
Fedele, P. [1 ]
Enrica, M. [1 ]
Rubino, D. [3 ]
Cinieri, S. [1 ]
机构：
[1] Osped A Perrino, Med Oncol, Brindisi, Italy
[2] Osped Sacro Cuore di Gesu Fatebenefratelli, Oncol, Benevento, Italy
[3] Policlin S Orsola Malpighi F Addarii, Oncol Med Addarii, Bologna, Italy
[4] Osped Sacro Cuore di Gesu Fatebenefratelli, Med Oncol, Benevento, Italy
[5] Azienda Osped Reg S Carlo Potenza, Oncol, Potenza, Italy
[6] Osped S Francesco, Oncol, Paola, Italy
[7] Osped Sacro Cuore di Gesu Fatebenefratelli, Oncol, Gallipoli, Italy
[8] AOU Santa Maria della Misericordia, Med Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
247P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy-An Italian multicenter experience.
    Lutrino, Stefania Eufemia
    Orlando, Laura
    Fontanella, Caterina
    Febbraro, Antonio
    Giampaglia, Marianna
    Zamagni, Claudio
    Scavelli, Claudio
    Giordano, Guido
    Basso, Enrico
    Quercia, Sara
    Quaranta, Annamaria
    Corbo, Claudia
    Romano, Rosangela
    Rubino, Daniela
    Caliolo, Chiara
    Campidoglio, Serena
    Bilancia, Domenico
    Barbieri, Elena
    Marino, Antonella
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
    Lutrino, Eufemia S.
    Orlando, Laura
    Febbraro, Antonio
    Giampaglia, Mariangela
    Zamagni, Claudio
    Schiavone, Paola
    Scavelli, Claudio
    Dima, Gianluca
    Fedele, Palma
    Giordano, Guido
    Bilancia, Domenico
    Quaranta, Anna Maria
    Rubino, Daniela
    Filippelli, Gianfranco
    Fontanella, Caterina
    Caliolo, Chiara
    Marino, Antonella
    Calvani, Nicola
    Ferrara, Pasqualinda
    Cinieri, Saverio
    TUMORI JOURNAL, 2020, 106 (04): : 301 - 305
  • [3] Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients: results from an Italian observational study
    Orlando, L.
    Lutrino, E. S.
    Giordano, G.
    Zamagni, C.
    Caliolo, C.
    Febbraro, A.
    Giampaglia, M.
    Dima, G.
    Rubino, D.
    Scavelli, C.
    Schiavone, P.
    Bilancia, D.
    Filippelli, G.
    Quaranta, A.
    Fedele, P.
    Mazzoni, E.
    Fontanella, C.
    Cinieri, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [5] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [6] Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience
    Kovalenko, E.
    Manzyuk, L.
    Gorbunova, V.
    Kolyadina, I.
    Bolotina, L.
    Zhilyaeva, L.
    Ponomarenko, D.
    Karabina, E.
    Mukhametshina, G.
    Khasanova, A.
    Ekaterina, R.
    Safarova, A.
    Manikhas, A.
    Volkonsky, M.
    Kramskaya, L.
    Karandeeva, T.
    Suslova, I.
    Popova, N.
    Evstigneeva, I.
    Shumskaya, I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S59 - S59
  • [7] Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer
    Sarici, Furkan
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (06): : 2562 - 2569
  • [8] Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer
    Kiba, Takayoshi
    Morii, Nao
    Takahashi, Hirotoshi
    Ozaki, Shinji
    Atsumi, Misao
    Masumoto, Fumi
    Shitakubo, Yoshimi
    Yamashiro, Hiroyasu
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (01) : 47 - 50
  • [9] Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)
    Shien, T.
    Ikeda, M.
    Ohtani, S.
    Hara, F.
    Takahashi, M.
    Tuji, H.
    Yoshitomi, S.
    Matsuoka, K.
    Ogasawara, Y.
    Taira, N.
    Doihara, H.
    Ohsumi, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
    Rosalba Torrisi
    Raffaella Palumbo
    Rita De Sanctis
    Patrizia Vici
    Giulia Valeria Bianchi
    Laura Cortesi
    Vita Leonardi
    Rossana Gueli
    Alessandra Fabi
    Maria Rosaria Valerio
    Anna Rita Gambaro
    Barbara Tagliaferri
    Laura Pizzuti
    Marina Elena Cazzaniga
    Armando Santoro
    Breast Cancer Research and Treatment, 2021, 190 : 103 - 109
12345